-
Baxter prepping for HyQvia launch with spinoff's success on the lineIt's been a long road for Baxter's ($BAX) primary immunodeficiency (PID) replacement therapy in the U.S., but the Illinois company is finally preparing to roll out the med in its home country. And wit2014/10/20
-
ViiV Healthcare’s HIV drug Triumeq obtains Canadian approvalViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to treat pat2014/10/17
-
Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infectionGilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype 1 in2014/10/17
-
WHO warns of 10,000 new weekly Ebola casesThe World Health Organisation (WHO) has warned West Africa may face up to 10,000 new Ebola cases per week within two months, due to the increasing number of patients. With a reported death rate of 702014/10/17
-
Helsinn’s Akynzeo obtains FDA approval to treat chemotherapy-induced nausea and vomitingSwitzerland-based Helsinn Healthcare has obtained US Food and Drug Administration approval for its fixed combination capsule Akynzeo to treat patients with chemotherapy-induced nausea and vomiting (CI2014/10/16
-
GSK starts unloading older meds by region, with $3B portfolio up for grabsEarlier this year, GlaxoSmithKline ($GSK) announced that it would sell off some of its older drugs to help revive profits and slim down a sagging portfolio. Now, the company is planning to put $3 bill2014/10/16
-
FDA grants a combo-med exclusivity wish. Why is that a problem?What's two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the prev2014/10/16
-
Pfizer Bulk Pharmaceutical Facility, SingaporeMore and more pharmaceutical companies are locating part of their manufacturing base to Singapore. The reasons for this are that operating costs and tax/financial incentives are considerably are sligh2014/10/15
-
CFDA Vice Minister Yin Li meets Country Head of U.S. FDA China OfficeOn September 11, 2014, Yin Li, Vice Minister of China Food and Drug Administration (CFDA), met with the delegation led by Chris Hickey, Country Head of U.S. FDA China Office, and Pam Bailey, President2014/10/15
-
National Drug Abuse Monitoring Annual Report (2013) issuedRecently, China Food and Drug Administration and the Office of China National Narcotics Control Commission jointly issued the National Drug Abuse Monitoring Annual Report (2013). The annual report a2014/10/15